Snip20160119_1.png

Hitachi Chemical Co. America, Ltd. to Acquire 100% of PCT - A Transformative Event for PCT and Hitachi Chemical

 

We are pleased today to announce a significant upcoming transformation for our company and enhancements to our capabilities to serve our valued clients. Hitachi Chemical Co. America, Ltd. (Hitachi Chemical), our collaborator and currently minority owner of PCT, has entered into an agreement with Caladrius Biosciences, majority owner of PCT, to purchase Caladrius’ remaining share of PCT, with an expected closing of the transaction in May 2017, subject to, among other closing conditions, Caladrius shareholder approval. I have included links to the press releases by Hitachi Chemical and by Caladrius Biosciences.

Safety First: Shipping Cell Therapy Materials

Cell therapies are at the forefront of saving lives – providing critical treatments to patients who might otherwise have very few viable options. Because these therapies are so unique, there are a multitude of complex challenges that must be overcome. Of particular concern is product potency. After the manufacturing process, the shipment of the final product is crucial to ensure the patient is treated with an efficacious therapy. Without a safe delivery of incoming material, the entire manufacturing process could be compromised, resulting in a lost batch or lost time, and could ultimately lead to no final product.

 

Challenges and Optimization of Apheresis Collection

On Thursday, February 23 from 2:00 – 3:30 PM EST, Sanjin Zvonic, PhD, PCT’s Senior Director, Business Leader, Clinical Cell Therapy Manufacturing, will be speaking as part of a panel on a webinar hosted by AABB titled “Apheresis Optimization in Gene and Immunotherapy Development in Non-Mobilized Patients and Donors.”

PCT Earns FACT Re-Accreditation for its Cell Therapy Development and Manufacturing Facilities

PCT has earned re-accreditation by the Foundation for the Accreditation of Cellular Therapy (“FACT”). This accreditation confirms that PCT operates in compliance with the FACT-JACIE International Standards for Cellular Therapy Product Collection, Processing and Administration at both its Allendale, New Jersey and Mountain View, California sites.

Current and Future Scale-Out Needs in Cell Therapy Manufacturing

The following is an excerpt from a paper originally published online in the journal Cytotherapy on October 26, 2016, entitled, “Bioreactors for cell therapies: Current status and future advances.” The paper’s authors are Shannon Eaker, Eytan Abraham, Julie Allickson, Thomas A. Brieva, Dolores Baksh, Thomas R.J. Heathman, Biren Mistry, and Nan Zhang.